Interestingly, targeting IL-17A itself was initially developed for IBD but resulted in exacerbated symptoms, and the approach has since then proven safe and effective for treating psoriasis and psoriatic arthritis [80, 81]. The gene discussed is IL17A; the disease is inflammatory bowel disease.